Abcam, ab258609, Human PSMD8 knockout HEK-293T cell lysate

Size: 1Kit
PSMD8 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon 1 and 22 bp deletion in exon 1.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon 1 and 22 bp deletion in exon 1.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-PSMD8, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PSMD8 also known as proteasome 26S subunit non-ATPase 8 is a component of the 19S regulatory particle of the proteasome complex. This protein has a molecular mass of approximately 37 kDa. It facilitates protein degradation by recognizing ubiquitin-tagged substrates important for maintaining protein homeostasis. Researchers have identified its expression in various tissues including liver kidney and heart and it plays a significant role in cellular processes that require regulated protein turnover.
Biological function summary
PSMD8 contributes to the assembly and function of the 26S proteasome which is a multi-subunit complex responsible for degrading ubiquitinated proteins. It acts as a part of the regulatory particle enabling substrate recognition and unfolding. Through its function PSMD8 is involved in the ubiquitin-proteasome system which is key in cellular regulation mechanisms such as cell cycle control apoptosis and DNA repair. This highlights its importance in maintaining cell function and integrity.
Pathways
Protein homeostasis and degradation represent important pathways in which PSMD8 participates. It plays a role in the ubiquitin-proteasome pathway interacting with proteins within this system like Rpn11 and Rpt5 which are also parts of the proteasome complex. Additionally the involvement of PSMD8 in the protein degradation pathway links it to the regulation of transcription factors influencing various signaling pathways that control cell proliferation and differentiation.
PSMD8 has implications in neurodegenerative diseases and cancer as disruptions in proteasome functions are often related to these conditions. Altered proteasome activity can lead to the accumulation of misfolded or damaged proteins which is a hallmark of neurodegenerative diseases such as Parkinson's disease. Moreover in cancer PSMD8's role in protein degradation can affect cell cycle regulation working in connection with proteins like p53. These relationships make PSMD8 an interesting target for therapeutic interventions in proteasome-related diseases.